Ezra Klein's column in yesterday's Washington Post on the Medicare prescription drug benefit discusses why costs in Part D have come in beneath expectations. He makes some fair points. But Ezra overlooks the program's unique design that is helping to keep costs far below initial projections and coverage affordable for beneficiaries.
Most Recent Posts
We're focused this week on the past 30 years of HIV/AIDS and how the disease - and with it, the world - has changed in those three decades.
But what does 30 years really mean?
To me, it's nearly a lifetime. To early patients who have survived and are with us today, it may feel like a miracle.
To help put it into context, some of my colleagues made an incredibly moving brief video about the timeline of AIDS research and advances.
AstraZeneca CEO David Brennan, in his role as President of the International Federation of Pharmaceutical Manufacturers and Associations, gave the
Unsurprisingly, coverage of the AIDS 30th anniversary has been heating up. On Friday on NPR's All Things Considered, University of Alabama-Birmingham's Dr. Michael Saag spoke about spending his entire career treating AIDS, as he began his residency in 1981.
Grady, my partner in blogging, is enviably vacationing in the south of France, so you'll be hearing even more from me in the next 10 days or so. I don't know who is luckiest: Grady, me or you...
Anyway, two topics will be front and center throughout the week: the progress we've made since HIV/AIDS was first formally recognized 30 years ago and the tremendous promise of personalized medicine. As you'll see, there are many common threads in these separate but very much entwined story lines.
Yesterday, June 5, was the 30th anniversary of the first time a medical journal mentioned patients suffering from the disease that we now know as HIV/AIDS.
CNN today ran a segment on the problem of counterfeit medicines.
It serves as a reminder that American patients currently enjoy peace of mind knowing that their prescription medicines are safe and effective, as determined by the US Food and Drug Administration (FDA), and not counterfeit.
Biopharmaceutical companies led to a nearly 18 percent increase in corporate philanthropy in 2010, according to an article published this morning by Reuters.
This week marks the beginning of the 2011 hurricane season. Experts are predicting one of the strongest seasons on record. The National Oceanic and Atmospheric Administration (NOAA), in its 2011 hurricane season forecast, predicts 12-18 named storms during the Atlantic hurricane season, with three to six becoming serious enough to be classified as major hurricanes.
Check out this op-ed by Illinois Chamber of Commerce Vice President of Government Affairs Todd Maisch in the Chicago Sun-Times. Maisch examines how a strong biopharmaceutical research sector can help grow the state's economy.
Over the weekend, The Washington Post ran an op-ed by Anthony Fauci, M.D., the director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, and one of the earliest pioneers in the field of HIV/AIDS research.
Over the last few weeks, Medicare has been front and center in the news. Elections and congressional votes have only reaffirmed that the program is highly regarded by seniors and the electorate.
A recent poll details this sentiment and shows voters will not react kindly to proposals that cut the Medicare program. The results are laid out in this Politico story.
There's a good piece over at Pharma Times On-line reminding us all of the work and giving by biopharmaceutical research companies to help the victims of the tsunami in Japan. The article notes that these critical contributions by medicine-makers are sometimes overlooked, with credit going to organizations and agencies providing direct services.